- Home
- BEAM
as 07-26-2024 4:00pm EST
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.1B | IPO Year: | 2020 |
| Target Price: | $45.64 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.95 - $49.50 | Next Earning Date: | 08-06-2024 |
| Revenue: | $360,911,000 | Revenue Growth: | 370.57% |
| Revenue Growth (this year): | -86.47% | Revenue Growth (next year): | -3.77% |
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Simon Amy | BEAM | Chief Medical Officer | Jul 1 '24 | Sell | $23.76 | 502 | $11,927.52 | 69,553 | SEC Form 4 |
| Simon Amy | BEAM | Chief Medical Officer | Jul 1 '24 | Sell | $22.95 | 748 | $17,166.60 | 68,805 | SEC Form 4 |
| Evans John M. | BEAM | CEO | Jun 27 '24 | Sell | $24.50 | 60,000 | $1,470,156.00 | 998,343 | SEC Form 4 |
| Simon Amy | BEAM | Chief Medical Officer | Apr 1 '24 | Sell | $32.13 | 7,157 | $229,954.41 | 86,590 | SEC Form 4 |
| Simon Amy | BEAM | Chief Medical Officer | Apr 1 '24 | Sell | $30.54 | 16,530 | $504,851.00 | 70,060 | SEC Form 4 |
| Evans John M. | BEAM | CEO | Apr 1 '24 | Sell | $32.13 | 18,102 | $581,617.26 | 1,058,343 | SEC Form 4 |
| Bellon Christine | BEAM | Chief Legal Officer | Apr 1 '24 | Sell | $32.12 | 3,401 | $109,240.12 | 104,594 | SEC Form 4 |
| Burrell Terry-Ann | BEAM | Chief Financial Officer | Apr 1 '24 | Sell | $32.12 | 5,446 | $174,925.52 | 70,137 | SEC Form 4 |
| Ciaramella Giuseppe | BEAM | President | Apr 1 '24 | Sell | $32.12 | 4,534 | $145,632.08 | 169,616 | SEC Form 4 |
| Evans John M. | BEAM | CEO | Mar 28 '24 | Sell | $33.86 | 60,000 | $2,031,402.00 | 998,262 | SEC Form 4 |
| FMR LLC | BEAM | Feb 13 '24 | Sell | $30.28 | 410 | $12,414.80 | 2,773,068 | SEC Form 4 | |
| FMR LLC | BEAM | Feb 13 '24 | Sell | $30.93 | 1,155 | $35,724.15 | 2,771,913 | SEC Form 4 | |
| FMR LLC | BEAM | Feb 13 '24 | Sell | $30.51 | 854,323 | $26,065,394.73 | 1,281,188 | SEC Form 4 | |
| FMR LLC | BEAM | Feb 13 '24 | Sell | $31.34 | 45,677 | $1,431,517.18 | 1,235,511 | SEC Form 4 | |
| Evans John M. | BEAM | CEO | Jan 31 '24 | Sell | $25.33 | 60,000 | $1,519,800.00 | 1,058,262 | SEC Form 4 |
| Bellon Christine | BEAM | Chief Legal Officer | Jan 3 '24 | Sell | $26.42 | 1,907 | $50,382.94 | 80,495 | SEC Form 4 |
| Bellon Christine | BEAM | Chief Legal Officer | Nov 20 '23 | Sell | $30.00 | 5,000 | $150,000.00 | 87,402 | SEC Form 4 |
| Bellon Christine | BEAM | Chief Legal Officer | Nov 20 '23 | Sell | $31.00 | 5,000 | $155,000.00 | 82,402 | SEC Form 4 |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
Zacks
12 hours ago
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Investor's Business Daily
2 days ago
Beam Therapeutics Stock Earns RS Rating Jump To 85
TipRanks
2 days ago
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
MT Newswires
3 days ago
Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy
MT Newswires
4 days ago
HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target
BioPharma Dive
10 days ago
Caribou lays off staff; Roche walks away from Relay
Zacks
10 days ago
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
MT Newswires
11 days ago
Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.